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Aim: To improve the patients postoperative pain experience using protective analgesia for patients
undergoing third molar surgery under day case general anaesthesia.
Material and methods: Patients were randomly allocated to a protective analgesia (1.6 g modiﬁed release
ibuprofen) or conventional analgesia (400 mg conventional ibuprofen) orally 2 h preoperatively. Surgical
model was third molar surgery. Postoperative outcomes of interest were pain intensity at 30 min, 1, 6, 24
and 48 h. The time to rescue analgesia, overall assessment of pain control, safety and tolerability proﬁles
were also recorded.
Results: 122 patients entered the study providing 98 evaluable patients for analysis. Patients in the
protective analgesia group reported more pain than those in the conventional group at 30 min, 1, 6 and
48 h following surgery, although this difference was only statistically signiﬁcant at the 30 min time point.
62.2% of patients required rescue analgesia within 6 h after surgery. The median time for patients who
had to take rescue analgesia was 3.1 h. Patients in the protective analgesia group reported a longer time
to rescue analgesia compared with those in conventional analgesia group. Overall, 91.7% of patients were
at least satisﬁed with their pain control.
Conclusion: There was no difference in the protective analgesia group compared with conventional anal-
gesia group in improving postoperative pain experience. A different protective analgesia regime may be
necessary,which employs amore aggressive andmultimodal strategy for postoperative painmanagement.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The concept of preemptive analgesia began with Crile in 1913
when he described a technique to eliminate preoperative fear and
tension. Crile advocated the use of generous premedication with
morphine and atropine, regional (procaine) block, and anaesthesia
by inhalation of nitrous oxide and oxygen in his theory to prevent
shock during surgery.1 The idea of preemptive analgesia was later
revived and described by Woolf, who demonstrated evidence for
the central component of post injury pain hypersensitivity in
a series of animal studies.2
Pain may be produced peripherally as a result of tissue damage
and inﬂammation (inﬂammatory pain); damage within the central
nervous system (neuropathic pain); or due to alterations in the
normal functions of the nervous system (functional pain).3 Pain
hypersensitivity can be a common postoperative complication. Pain
sensation at the surgical sitemay be increased and persist long afterS.L. Yong), paul.coulthard@
ciates Ltd. Published by Elsevier Ltnoxious stimuli are removed (hyperalgesia). Pain hypersensitivity
may also result in pain sensation being felt in other areas close to
the surgical site (allodynia). There are two mechanisms involved in
pain hypersensitivity: central and peripheral sensitisation.
1.1. Peripheral sensitisation
Peripheral sensitisation is the reduction in the threshold and
increased responsiveness of nociceptive afferent peripheral termi-
nals.4 Peripheral nociceptors become more responsive with
repeated application of noxious stimuli. Sensitivity of the periph-
eral nociceptors can be further enhanced by several tissue factors
and inﬂammatory mediators released in the course of tissue
injury.5 During inﬂammation and tissue injury, prostaglandins and
leukotrienes are released directly activating the ends of peripheral
nociceptors leading to sensitisation and increasing responsiveness
to other stimuli.4
1.2. Central sensitisation
Following peripheral tissue injury, chemical changes can occur
within the central nervous system. A variety of neurotransmittersd. All rights reserved.
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Substance P in turn induces the release of excitatory amino acids
such as glutamate and aspartate, which are involved in the
increased excitability of N-methyl-D-aspartate (NMDA) receptor
sites within the spinal cord. It has been proposed that activation of
NMDA receptor sites by the excitatory amino acids enhance
depolarisation, making the neurons more responsive and thereby
leads to ampliﬁcation and increased duration of pain.6 Central
sensitisation or ‘wind-up’ is used to describe the enhanced excit-
ability and sensitisation of dorsal horn cells induced by the above
mechanisms.7
Preemptive analgesia aims to minimise or prevent onset of
peripheral and central sensitisation by employing various inter-
ventions at different stages of the pain pathway. Although the
evidence for preemptive analgesia is promising in animal studies,
there is still controversial evidence of success in reducing post-
operative pain in human trials. This may be due to variations in the
deﬁnition of preemptive analgesia.
Kissin et al. found that the deﬁnition for preemptive analgesia
was far from uniform. He identiﬁed three different deﬁnitions for
preemptive analgesia used in current clinical trials. Preemptive
analgesia has been deﬁned as treatment that:
1. starts before surgery;
2. prevents the establishment of central sensitisation caused by
incisional injury (covers only the period of surgery);
3. prevents the establishment of central sensitisation caused by
incisional and inﬂammatory injuries (covers the period of
surgery and the initial postoperative period).
In order to demonstrate the maximum beneﬁts of preemptive
analgesia in clinical trials, two conditions should be met. Firstly,
the intervention should be effective in suppressing afferent input
and of sufﬁcient duration of action, covering the initial post-
operative period. Secondly, combined treatment modalities should
be employed to maintain preemptive effects and reverse central
sensitisation.8 This is a concept called protective analgesia. Several
other terms have also been used e ‘balanced multimodal anal-
gesia’ and ‘preventive analgesia’ but all employ a similar
concept.9,10 The treatment approach aims to control the develop-
ment of central sensitisation in the postoperative period. This
advocates the use of multimodal techniques with several drugs to
attenuate peripheral and central hypersensitivity and with
a sufﬁcient duration of treatment.11 Although nociceptive pain is
often regarded as the key feature of acute postoperative pain, the
focus should be redirected from the timing of perioperative
analgesia to protective analgesia. Aggressive and multimodal
strategy for postoperative pain management should therefore be
adopted.12
The aim of this study was to investigate the efﬁcacy of
protective analgesia in improving the postoperative pain expe-
rience. We compared the combined effects of sustained release
ibuprofen and bupivacaine nerve block with the combined
effects of conventional ibuprofen and bupivacaine nerve block.
Whilst the effect of the local anaesthesia would make it more
difﬁcult to demonstrate difference between types of ibuprofen,
this design was chosen to limit the variables under investiga-
tion. Third molar surgery was the chosen surgical model as this
is validated model for pain clinical trials. Our hypothesis
was that the combined effects of sustained released ibuprofen
and bupivacaine nerve block would reduce the proportion
of patients with moderate to severe pain compared to the
combined effects of conventional ibuprofen and bupivacaine
nerve block. The safety and tolerability proﬁle were also
documented.2. Materials and methods
2.1. Study design and patient selection
The setting for this double blind, active control, randomised
clinical trial was the Oral Surgery Day Case Unit at Central Man-
chester University Hospitals NHS Foundation Trust. The study was
approved by the Regional Ethics Committee and the Medicines and
Healthcare products Regulatory Agency (MHRA).
Patients were considered eligible for study inclusion if they
were male or female, aged 18 and over, ASA I or II, able to under-
stand and cooperatewith the requirements of the protocol and able
and willing to exercise an appropriate written informed consent.
Patients were excluded from participating in the study if they had
a known hypersensitivity to NSAIDs, paracetamol or bupivacaine,
or if they were pregnant. Patients were also excluded if they had
used analgesics within 48 h prior to the day of surgery, alcohol
within 24 h prior to the day of surgery or had a suspected or known
history of alcohol or drug abuse.
2.2. Sample size
We calculated that 48 patients in each group would be required
to detect the difference between Group 1 proportion of 0.55 and
a Group 2 proportion of 0.25 (odds ratio of 0.273). The statistical
power of the study was 80%. The sample size was based on our
primary outcome measure of proportion of patients requiring
rescuemedicationwithin 6 h of surgery. Seymour et al.13 previously
reported this outcome at 55% in their 400 mg ibuprofen group and
Morse et al.14 reported rofecoxib, with similar efﬁcacy but longer
duration than ibuprofen, at 25%. We recruited 122 patients to
produce 96 evaluable patients.
2.3. Allocation concealment and blinding
Patients were allocated to the protective analgesia group or
conventional analgesia group according to computer generated
randomisation code that were concealed in sealed envelopes and
opened 2 h before surgery. Each patient was given a unique iden-
tiﬁcation number based on the randomisation information and this
code was held by the hospital pharmacist. The protective analgesia
group received 1.6 gmodiﬁed release ibuprofen (2 800 mg) orally
2 h prior to surgery and the conventional analgesia group received
conventional release 400 mg ibuprofen (2 200 mg) orally 2 h
prior to surgery. The study medication was administered by
a qualiﬁed nurse or other study staff member blinded to study
assessments.
All participants and investigators were blinded to the treatment
allocation throughout the study period. Only the statistician who
generated the random numbers and hospital pharmacist had access
to the randomisation code but none were involved in the recruit-
ment, allocation or assessment of the study participants.
2.4. Surgery
Third molar surgical technique and general anaesthetic tech-
niques were standardised as far as possible and prophylactic anti-
biotics, 200 mgmetronidazole, 8 hourly for 5 days, were prescribed
for all patients. Surgery was undertaken by ﬁve experienced
surgeons using standard thirdmolar mucoperiosteal ﬂapwith bone
removal with a surgical bur cooled with normal saline. An anaes-
thetic protocol was formulated to eliminate possible confounding
drugs which may give a preemptive effect by delivery of analgesics
during induction andmaintenance of general anaesthesia (Table 1).
Patients in both groups received 5 ml bupivacaine 0.5% with
Table 1
Anaesthetic protocol.
Induction Sleep dose of propofol
Maintenance Air/Oxygen/Sevoﬂurane
Airway LMA/COERTT/CNETT as indicated (NB. A nasal tube makes
the placement of the inferior dental nerve block much easier)
Muscle relaxant Mivacurium 0.2 mg/kg if using IPPV
Other drugs 1. Anti-emetics as required (but not Dexamethasone)
2. Neostigmine/Glycopyrrolate as required
Drugs to be
avoided
1. All opiods (a small bolus of remifentinil or alfentanil to
facilitate intubation should be ok if really necessary)
2. Non-opiod analgesics (tramadol, paracetamol, NSAID’s)
3. Dexamethasone
4. Nitrous Oxide
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tration of long buccal nerve per side immediately prior to surgical
incision.
2.5. Pain measures
The outcomes of interest were as follows:
2.5.1. Pain intensity
Postoperative pain intensity was measured using a 10 cm Visual
Analogue Scale labelled ‘no pain’ to ‘worst pain imaginable’ at
30 min and 1, 6, 24 and 48 h following surgery. Surgery end point
was deﬁned as the time when intravenous drugs or anaesthetic
gases for the maintenance of anaesthesia were stopped. Following
at least 1-h observation period after surgery, patients were dis-
charged from the day case unit based on their recovery as assessed
by nursing staff. A pain diary with a stamped return address
envelope was provided and a 3 day supply of codeine/paracetamol
(30/500) to be used as rescue analgesia as required.
2.5.2. Time to rescue analgesia
Rescue analgesia (codeine/paracetamol) was administered at
the request of the patients after surgery. The number of patientsAssessed for eligibility 
Analyzed (n = 50) 
Excluded from analysis (n = 8) 
Reasons: Lost to follow-up (n = 4) 
      Failed ID block (n = 4) 
Lost to follow-up (n = 4) 
Discontinued intervention (n = 4) 
Reason: Failed ID block 
Allocated to intervention (n = 59) 
Received allocated intervention (n = 58) 
Did not receive allocated intervention (n = 1) 
Reason: Can’t tolerate study medication 
Allocatio
Analysis
Follow-U
Enrollmen
Randomized (n
Fig. 1. CONSORT ﬂrequiring rescue analgesia as well as the time it was taken was
recorded.
2.5.3. Overall assessment of pain control
At the end of the 48-h period, patients were asked to provide an
overall assessment of treatment efﬁcacy with regard to pain
experience using a numerical rating scale. The scale ranged from
0¼ Extremely poor to 10¼ Excellent.
The initial assessments were carried out by the study investi-
gator who was not involved in the administration of the study
medications. Subsequent assessments were carried out by patients
self reported pain intensity using a pain diary.
2.6. Statistical methods
The t-test, z-test and Chi-square test were applied for differ-
ences in mean and proportion between groups. The analysis of time
to rescue medication was analysed by log-rank test. The median
time estimations and 95% conﬁdence intervals on the median time
for the time variables was provided by using KaplanMeier.We used
SPSS (version 15) for statistical analysis.
3. Results
We invited and screened a total of 122 patients in order to
achieve number needed for each group based on the power
calculation. Of these, 12 patients were excluded for not meeting the
study criteria and 9 did not return the pain diary (Fig. 1). The
reasons for exclusion are shown in Table 2.
Successful inferior alveolar nerve block was demonstrated by
patient’s reported signs of altered lip and gingival sensation. Seven
patients were excluded as not demonstrating signs of successful
inferior alveolar nerve block. Four patients withdrew consent as
they were unable to tolerate taking the study medication. Three
patients were cancelled for failing to comply with starvation times
prior to general anaesthesia and one patient suffered broncho-
spasm during induction of anaesthesia and surgery was
abandoned. (n = 122) 
Excluded  (n = 3) 
Reason: Not starved for GA  
Lost to follow-up (n = 5) 
Discontinued intervention (n = 3) 
Reason: Failed ID block 
Allocated to intervention (n = 60) 
Received allocated intervention (n = 56) 
Did not receive allocated intervention (n = 3) 
Reasons: Can’t tolerate study medication (n = 3) 
      Asthma attack (n = 1)
Analyzed (n = 48) 
Excluded from analysis (n = 8) 
Reasons: Lost to follow-up (n = 5) 
      Failed ID block (n = 3)  
n
 
p 
t 
 = 119) 
ow diagram.
Table 2
Reasons for exclusion from study.
Number (%) of patients Protective analgesia Conventional analgesia
Unable to tolerate medication 1 3
Unsuccessful nerve blockade 4 3
Did not return pain dairy 4 5
Bronchospasm event 0 1
Total 9 (15.2%) 12 (20%)
Table 3
Demographic details of patients where age is expressed as mean SD.
Characteristic Protective analgesia Conventional analgesia
Number of patients 50 48
Male 13 16
Female 37 32
Age (years) 28.82 6.26 28.71 5.8
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(29.6%) and 69 females (70.4%) ranging from 20 to 55 years, with
a mean age of 28.776.01 years. The patients’ demographic detail
for each group is shown in Table 3.
3.1. Pain intensity
Patients in the protective analgesia group reported more pain
than those in the conventional analgesia group at 30 min, 1, 6 and
48 h following surgery, although this difference was only statisti-
cally signiﬁcant at the 30 min time point. The mean pain intensity
scores throughout the 48 h period are shown in Table 4 and Fig. 2.
Patients self report pain intensity scores were categorised as
follows. This validated data transformation enables a more sensi-
tive analysis:15
0¼No pain
1e4¼Mild pain
5e6¼Moderate pain
7e10¼ Severe pain
There were more patients with moderate to severe pain in the
protective analgesia group at 30 min,1 h and at 48 h. The difference
was not statistically signiﬁcant for any of the time intervals (Table 5
and Fig. 3).
3.2. Time to rescue analgesia
Over the 48 h period, 11 patients (11.2%) did not require rescue
analgesia. There were more patients in the conventional analgesia
group who did not require rescue analgesia but the difference was
not signiﬁcant (Chi-square test, p¼ 0.366). Table 6 shows the
rescue analgesia requirement over 48 h between the two groups.Table 4
Pain intensity scores over 48 h period.
VAS 30 min 1 h
Protective analgesia
n¼ 50
Mean SD (mm) 26.08 29.54 23.5
Conventional analgesia
n¼ 48
Mean SD (mm) 15.77 20.37 17.4
Difference (95% CI) mm 10.31
(0.30, 20.32)
6.16
(3
P value (t-test) 0.048 0.20
P values of the original pain intensity scores with level of statistical signiﬁcance set at 0The median time for patients who had to take rescue analgesia
for the duration of the study was 3.1 h. Patients in the protective
analgesia group reported a longer time to rescue analgesia (median
3.2 h) compared with those who received conventional ibuprofen
(median 2.7 h). The difference, however, was not statistically
signiﬁcant (log-rank test, p¼ 0.386). The proportion of patients
taking rescue analgesia over the 48 h period is shown in the
survival curves in Fig. 4. The results indicate that the estimated
cumulative probability of rescue analgesia requirement was more
for patients in the conventional analgesia group until about 8 h.
Thereafter, the estimated cumulative probability of rescue anal-
gesia requirement was more for patients in the protective analgesia
group.
There were 61 (62.2%) patients requiring rescue analgesia
within 6 h following surgery. There were 29 (58%) patients in the
protective analgesia group who required rescue analgesia
compared to 32 (66.7%) patients in the conventional analgesia
group but the difference was not signiﬁcant (Chi-square test,
p¼ 0.701). In both groups, there were a high number of patients
with no or mild pain reported to require rescue medication. There
was no signiﬁcant difference in the median time to rescue medi-
cation between the two groups (Table 7).
3.3. Overall assessment of pain control
Patients rated their overall satisfaction about pain control on
a numerical rating scale. The mean reported score about satisfac-
tion with pain control for protective analgesia group was 7.6,
whereas for conventional analgesia group it was 7.38 (t-test,
p¼ 0.606). Patient self report assessment of pain control was cat-
egorised as follows:
0¼ totally dissatisﬁed
1e4¼ dissatisﬁed
5e7¼ satisﬁed
8e10¼ excellent
A higher proportion of patients were at least satisﬁed with their
pain control in the protective analgesia group (48, 96%) compared
to 42 (87.5%) in the conventional analgesia group but the difference
was not signiﬁcant (Fig. 5). This is similarly reﬂected by the number
of patients who were not satisﬁed with their pain control, with
a much lower proportion 2 (4%) in the sustained released ibuprofen
group compared to 6 (12.5%) in the conventional ibuprofen group.
3.4. Safety proﬁle and tolerability
Overall, the safety proﬁle of both sustained release ibuprofen
and conventional ibuprofen was good and well tolerated. One
patient with asthma but no known history of intolerance to
ibuprofen suffered bronchoconstriction during the induction of
general anaesthesia. The patients reported side effects is shown in
Table 8.6 h 24 h 48 h
9 25.13 26.55 24.02 25.04 23.77 25.14 22.81
3 22.63 25.14 23.68 26.36 22.79 23.65 23.57
.30, 15.62)
1.41
(8.03, 10.85)
1.32
(10.54, 7.90)
1.49
(7.70, 10.68)
7 0.771 0.779 0.752
.05.
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Fig. 2. Graph of mean pain intensity scores over 48 h period.
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Fig. 3. Graph showing proportion of patients with moderate to severe pain over 48 h.
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Patients were given a choice of telephone or clinic follow-up
assessment at 1 week after surgery. All patients preferred and
opted for telephone follow-up. This was carried out by the study
investigator. Patients who had not returned the pain diary at this
point were reminded to do so during the telephone follow-up. A
total of 9 (9.2%) patients failed return the pain diary despite further
attempts to contact patients by telephone. We also wrote to the
patients who were unable to be contacted by telephone with
a further pain diary and a letter to emphasise the importance of the
study.
4. Discussion
The objective of this randomised clinical trial was to investigate
the efﬁcacy of protective analgesia using the combined effects of
sustained release ibuprofen and bupivacaine nerve block in atten-
uation of postoperative pain using third molar surgery under day
case general anaesthesia as the surgical model. The efﬁcacy was
compared with a similar group receiving conventional ibuprofen.
No difference was found in the attenuation of postoperative pain
between sustained release ibuprofen and conventional ibuprofen
groups.
Third molar surgery is a recognised clinical model for evaluating
oral analgesics as postoperative pain is predictable and easily
reproducible.16 Surgery may be standardised since the variation in
duration and severity of surgery do not affect the degree of post-
operative pain experienced. Five surgeons of similar experience
performed the surgeries using a standardised technique. Ran-
domisation was by patient and not stratiﬁed by surgeon. This is
a potential limitation to our study.
The analgesic efﬁcacy of selective COX-2 inhibitors has been
demonstrated in single dose dental pain studies resulting in less
pain, longer time to needing rescue analgesia as well as less anal-
gesic consumption. The beneﬁts over conventional NSAIDs include
selective inhibition of COX-2 enzyme as well as analgesic effect for
up to 24 h with a single dose, reducing the risk of over dosage andTable 5
Number of patients with moderate to severe pain over 48 h.
30 min
Protective analgesia (n ¼ 50) Moderate to severe pain 14
(28%)
Conventional analgesia (n¼ 48) Moderate to severe pain 7
(14.6%)
Odds ratio (95% CI) 2.28
(0.83, 6.26)
Z value (signiﬁcant) 1.44 (no)
Z value of difference in proportions between groups with conﬁdence level at 95%.toxicity. Pain following third molar surgery is usually most severe
between 6 and 8 h following surgery.17 This longer duration of
action also allows analgesic effects of selective COX-2 inhibitors to
be extended into the postoperative period, an ideal property for
protective analgesia. However, selective COX-2 inhibitors are not
approved for routine use of postoperative dental pain due to
increased risk of cardiovascular events. As a result, several COX-2
preparations have been withdrawn from the market. Sustained
release ibuprofen has a similar mode of action to ibuprofen.
Preemptive use of conventional ibuprofen has been shown to be
effective in reducing postoperative pain.18e20 Sustained release
ibuprofen, on the other hand, has a longer duration of action of up
to 24 h compared to 6 h for conventional ibuprofen.21 The effec-
tiveness of sustained release ibuprofen over conventional
ibuprofenwas demonstrated in a study conducted by O’Connor and
colleagues.22 However, no studies investigated and compared the
preemptive use of sustained release ibuprofen with conventional
ibuprofen. Several studies also showed the effectiveness of bupi-
vacaine block on reducing postoperative pain following third molar
surgery. Our hypothesis was that the group receiving sustained
release ibuprofen combined with the effects of bupivacaine nerve
block would show reduced postoperative pain following surgery.
In this study, we found 62.2% of patients needing rescue anal-
gesia within 6 h following surgery. Although there were fewer
patients in the protective analgesia group needing rescue analgesia,
the difference was not signiﬁcant. The ﬁndings were similar to that
of Morse et al. who compared the preemptive analgesic effects of
rofecoxib to ibuprofen and placebo in a randomised double blind
clinical trial in patients undergoing lower third molar surgery.14
They found no signiﬁcant difference between rofecoxib and
ibuprofen in reducing postoperative pain and in the number of
patients needing rescue analgesia.
Patients in the protective analgesia group reported a longer
median time to rescue analgesia over the 48 h investigation period.
Despite the longer duration of action of sustained release ibuprofen,
the time to rescueanalgesiawasnot signiﬁcantlydifferent compared
to the conventional analgesia group. Overall, our intervention
delayed the requirement for rescue analgesia to a median time of1 h 6 h 24 h 48 h
12
(24%)
11
(22%)
10
(20%)
11
(22%)
5
(10.4%)
11
(22.9%)
12
(25%)
8
(16.7%)
2.71
(0.87, 8.41)
0.95
(0.37, 2.45)
0.75
(0.29, 1.94)
1.41
(0.51, 3.88)
1.65 (no) 0.13 (no) 0.35 (no) 0.41 (no)
Table 6
Time to rescue analgesia requirement over 48 h.
Time to rescue medication (mins) Protective
analgesia
Conventional
analgesia
Number of patients who used
rescue analgesia
46 (92%) 41 (85.4%)
Minimum 20 17
Median 192 (3.2 h) 162 (2.7 h)
Number of patient who did
not require rescue analgesia
4 7
Odds ratio (95% CI) 1.96 (0.53, 7.19)
P value (chi-square) 0.366
Table 7
Time to rescue analgesia requirement within 6 h.
Time to rescue medication (mins) Protective
analgesia group
Conventional
analgesia group
Number of patients who
used rescue medication
29 (58%) 32 (66.7%)
Minimum 20 17
Median 100 (1.7 h) 117.5 (1.9 h)
Number of patients with
no or mild pain
18 (62%) 23 (71.8%)
Number of patient who did not
require rescue medication
21 16
Odds ratio (95% CI) 0.69 (0.30, 1.57)
P value (chi-square) 0.701
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pretreatmentwith rofecoxib50 mghadamuchextendedmean time
to rescue analgesia of 11 h.23 However, the sample size of this study
was small and common among other studies; patients were only
allowed rescue analgesiawhenpostoperative pain reached a certain
threshold, typically a VAS score of 30 or more. Patients in our study
were not restricted by this threshold and were allowed to take
rescue analgesia at any time depending on individual’s pain toler-
ance and perception. This may explain the shorter time to needing
rescue analgesia in our study.
It is common for anaesthetists to utilise opioids and other non-
opioid analgesics perioperatively for the maintenance of anaes-
thesia, which may mask the effects on the intervention assessed.
This may be one of the reasons for previous clinical trials for failing
to show any preemptive effects of NSAIDs.24 We used a speciﬁc
anaesthetic protocol which had no analgesia component for the
induction and maintenance of general anaesthesia. This gave
a more accurate assessment and true account of the efﬁcacy of our
intervention.
As with the proportion of patients needing rescue analgesia and
time to rescue analgesia, pain intensity did not differ signiﬁcantly
between the protective analgesia and conventional analgesia
groups. In chronic pain studies, sustained release ibuprofen has
been shown to provide better efﬁcacy with added convenience of
single dosing but this was not the case in this acute pain setting.
The peak plasma concentration following initial dosing of sustained
release ibuprofen and conventional ibuprofen are very similar.25 No
clinically signiﬁcant differences can be observed most likely as
a result of similarities in the pharmacokinetics of both drugs. TheFig. 4. Survival curves for sustained release ibuprofen and conventional ibuprofen,
representing the proportion of patients in each group who did not require rescue
analgesia.preemptive effects of sustained release ibuprofen do not seem to be
comparable to that of the selective COX-2 inhibitor, rofecoxib. A
systematic review was conducted on individual patient meta-
analysis of single dose rofecoxib in postoperative pain. It was found
that single dose of 50 mg rofecoxib had comparable analgesic
efﬁcacy to ibuprofen 400 mg over 6 h. The NNT for rofecoxib was
fairly constant over a 24 h period whereas with ibuprofen, the NNT
increased sharply after 6 h.26 This may explain why sustained
release ibuprofen was no more effective than conventional
ibuprofen in our clinical trial and that it did not achieve the same
preemptive effects as with rofecoxib. A much higher loading dose
may be required to achieve a signiﬁcant preemptive effect for
sustained release ibuprofen. Increasing the loading dose would
however inevitably increase the risk of adverse effects.
It was surprising to ﬁnd such high postoperative pain scores in
both groups despite administrating a local anaesthetic nerve block.
This suggests that there is merit to using preoperative ibuprofen
even when using intraoperative local anaesthesia, consistent with
the theory of protective analgesia. The duration of action of bupi-
vacaine has been reported to be up to 8 h.27e29 It has been shown to
reduce postoperative pain in patients undergoing lower thirdmolar
surgery by decreasing the development of central hyperexcit-
ability.30,31 However, it is often difﬁcult to ensure that a true infe-
rior alveolar block has been achieved whilst patients is under
general anaesthetic. This is a limitation to our study where
a subjective assessment was carried out with our patients based on
reported alteration in lip and gingival sensation. An altered lip and
gingival sensation however, may not necessarily indicate a sufﬁ-
cient inferior alveolar nerve block and attenuation of central
hyperexcitability. A more accurate assessment using plasma beta-
endorphin levels, giving a better indication of the nociceptive
pathway and efﬁcacy of the inferior alveolar nerve block, may have
been helpful.
Seven patients in our study failed to demonstrate a successful
inferior alveolar nerve block and were excluded from the study and
analysis. An intention to treat analysis could not be performed as0
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Fig. 5. Overall rating of pain control.
Table 8
Number of reported side effects.
Events Protective analgesia Conventional analgesia
Headache 1 1
Dizziness 1 2
Nausea and vomiting 1 5
Swelling 6 4
Alveolar osteitis 0 1
Numb tongue 2 5
Bronchospasm event 0 1
Total 11 (22%) 19 (39%)
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recorded. We acknowledge that this is a limitation to our study.
However, these 7 patients were almost equally distributed between
the 2 groups and in order to evaluate the true effects of protective
analgesia; patients are required to have a successful inferior alve-
olar nerve block. Therefore, the exclusion of these patients as per
protocol would not have a signiﬁcant effect on the analysis.
Prolonged alteration of lip and gingival sensation may be
unpleasant experience but none of the patients in our trial reported
signiﬁcant morbidity associatedwith this. Therewere no prolonged
or unexpected adverse events reported in either treatment groups.
All reported side effects resolved spontaneously without additional
intervention. One patient developed bronchospasm during induc-
tion of anaesthesia. The symptoms spontaneously resolved
following administration of oxygen and bronchodilator. This
patient had no history of asthma and did not report any sensitivity
to NSAIDs. The patient had previously used ibuprofen onmore than
one occasion without any side effects. The bronchospasm was
believed to be related to the patient’s history of smoking.
The proportion of patients lost to follow-up in our studywas 9.2%.
Despite efforts to contact these patients, we were unable to retrieve
information required. A lost to follow-up of more than 20% is gener-
ally considered of concern to validity.32 However, further strategies
could possibly have been employed to minimise the number lost to
follow-up such as ﬁnancial incentives for the patients.
5. Conclusion
We were unable to demonstrate a statistically signiﬁcant
improvement in the pain experience using sustained release
ibuprofen and bupivacaine nerve block as protective analgesia
when compared to a conventional analgesic drug regime for
patients undergoing third molar surgery.Conﬂict of interest
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